Moderna Gets FDA Approval For Updated COVID-19 Vaccines Targeting LP.8.1 Variant Of SARS-COV-2

Moderna Inc MRNA:

• MODERNA RECEIVES U.S. FDA APPROVAL FOR UPDATED COVID-19 VACCINES TARGETING LP.8.1 VARIANT OF SARS-COV-2

• MODERNA: UPDATED FORMULA FOR SPIKEVAX IS NOW APPROVED FOR INDIVIDUALS 6 MONTHS THROUGH 64 YEARS OF AGE

• MODERNA: MNEXSPIKE, CO'S NEW COVID-19 VACCINE, IS APPROVED FOR INDIVIDUALS 12 THROUGH 64 YEARS OF AGE